MannKind Reports Q3 2026 Revenue Growth Driven by Furoscix and scPharma Acquisition
MannKind (MNKD) reported a strong third quarter for 2026, with total revenue reaching $101.9 million, a 24% increase year-over-year. This growth was primarily fueled by the successful acquisition of scPharma, which drove commercial product revenue up 102%, and robust royalty growth from Tyvaso DPI. The company also saw significant momentum with its Furoscix product following the launch of the ReadyFlow formulation. Despite a GAAP net loss of $23.2 million due to noncash acquisition expenses, the company's Non-GAAP performance showed marked improvement. Management highlighted strong pediatric adoption for Afrezza and provided an optimistic outlook for Furoscix in Q4, estimating revenue of approximately $38 million. However, leadership noted challenges regarding Medicare deductible resets and resource reallocation that impacted adult Afrezza sales.
Tickers: $MNKD
Topics: Acquisition Impact Net Loss Product Launch Revenue Growth